ICON PLC (ICLR) Stock AnalysisICLRICON PLC

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals. It operates in the Healthcare sector (COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH industry).

Currently, ICON PLC (ICLR) is trading at $164.17, which is below the analyst price targets of $185 and $195, indicating potential upside. However, the RSI is at 44.96, suggesting it is nearing oversold territory but not yet a strong buy signal. The forward P/E ratio of 14.75 is attractive compared to its current P/E of 38.59, indicating better value going forward. The main risk is the recent negative earnings report with a net income drop to -110.14 million in Q4 2025, which raises concerns about profitability.

15 analysts cover ICLR: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 202.67.